SAN FRANCISCO — An implantable cardioverter defibrillator (ICD) with a lead system that inserts just below the sternum performed promisingly in a recent early experience that sets the stage for a more ...
SAN FRANCISCO, CA—The subcutaneous implantable cardioverter-defibrillator (S-ICD; Boston Scientific) prevents most of the major lead-related complications seen with a transvenous system, the ATLAS ...
Please provide your email address to receive an email when new articles are posted on . Transvenous ICD leads are associated with tricuspid regurgitation compared with subcutaneous ICDs. More research ...
NATICK, Mass., /PRNewswire/ -- Boston Scientific Corporation has conducted the first implant in the clinical trial of the next generation ACUITY™ X4 left-ventricular (LV) pacing leads and RELIANCE™ ...
Box 1. Indications for transvenous lead extraction. Complete device and lead removal is recommended in all patients with definite CIED system infection, as evidenced by valvular endocarditis, lead ...
Adding to the Medtronic portfolio of catheter-based lead solutions, the novel OmniaSecure defibrillation lead allows for precise delivery and placement in the right ventricle Heart Rhythm 2025: ...
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--AtaCor Medical, Inc. announced today that it has completed enrollment in its initial acute Extravascular Implantable Cardioverter Defibrillator (EV-ICD) study.
Patients with intracardiac shunts might at some point require a pacemaker or an implantable cardioverter–defibrillator (ICD). These patients may have numerous thrombotic risk factors, however, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results